Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 6CNS 5Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1

Conditions

Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Endodermal Sinus Tumor 1Carcinoma, Embryonal 1

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × etoposide phosphate × Genitourinary × Clear all
NCT00301782 2013-08-26

Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors

National Cancer Institute (NCI)

Phase 2 Completed
88 enrolled
Genitourinary

Testicular Germ Cell Tumor, Teratoma, Testicular Neoplasms, Carcinoma, Embryonal, Endodermal Sinus Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡